Clinical Trial Update: The Study of an Investigational Drug, Patisiran (ALN-TTR02), for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis in Participants Who Have Already Been Treated With ALN-TTR02 (Patisiran) [Phase 3]

View source ↗

Summary

Phase 3 trial update for patisiran in patients with transthyretin-mediated amyloidosis who have already been treated with patisiran; study completed with result…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Amyloidosis
• Transthyretin Amyloidosis

Drugs mentioned

• Patisiran (patisiran)

Snippet

Sponsor: Alnylam Pharmaceuticals | Conditions: Amyloidosis | Phase 3 | Status: COMPLETED | Results posted: 2023-12-06